期刊
INTERNATIONAL JOURNAL OF PHARMACEUTICS
卷 642, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.ijpharm.2023.123206
关键词
Flavonoids; Microencapsulated delivery system; Oxidative stress; Nuclear factor-kappa B; Inflammatory bowel disease
Improved therapies for inflammatory bowel diseases are needed. The researchers investigated the activity of trans-chalcone (T) and developed microcapsules containing T for colitis treatment. In vitro experiments showed controlled release of T in simulated intestinal fluid. In vivo experiments demonstrated that MT significantly improved colitis outcomes and reduced colon damage.
Improved therapies for inflammatory bowel diseases are sorely needed. Novel therapeutic agents and the development of controlled release systems for targeted tissue delivery are interesting approaches to overcome these barriers. We investigated the activity of trans-chalcone (T) in acetic acid-induced colitis in mice and developed, characterized, and determined the therapeutic effect of pectin/casein polymer microcapsules containing T (MT) in a colitis mouse model. In vitro, compound release was achieved in simulated intestinal fluid but not in the simulated gastric fluid. In vivo, since T at the dose of 3 mg/kg but not 0.3 mg/kg ameliorated colitis, we next tested the effects of MT at 0.3 mg/kg (non-effective dose). MT, but not free T at 0.3 mg/kg, significantly improved colitis outcomes such as neutrophil recruitment, antioxidant capacity, cytokine production, and NF-kappa B activation. This translated into reduced macro and microscopic damage in the colon. T release from the microcapsules is mediated by a pH-dependent and pectinase-regulated mechanism that provide controlled and prolonged release of T. Moreover, MT lowered the required dose for T therapeutic effect, indicating that could be a suitable pharmaceutical approach to colitis treatment. This is the first demonstration that T or MT is effective at reducing the signs of colitis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据